Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 0.74 |
| ▸ | ICAM1 | P05362 | 20/20 | 0.74 |
| ▸ | ITGAL | P20701 | 20/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12704679 | 0.93 | ITGB2 (0.85) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL4546553 | 0.91 | ITGB2 (0.87) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL20833710 | 0.91 | ITGB2 (0.87) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL20833713 | 0.86 | ITGB2 (0.87) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL16846644 | 0.86 | ITGB2 (0.85) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL22476466 | 0.85 | ITGB2 (0.78) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL4756016 | 0.85 | ITGB2 (0.84) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL17991423 | 0.85 | ITGB2 (0.84) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL17991463 | 0.85 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL23422265 | 0.84 | ITGB2 (0.89) | ITGB2ICAM1ITGALCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331711-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | BAUSCH + LOMB IRELAND LIMITED (IE) | 2023-10-19 | — | — | US | disclosed |
| US-20180118726-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | SARCODE BIOSCIENCE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20160368902-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | SARCODE BIOSCIENCE INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-9447077-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150336939-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | SARCODE BIOSCIENCE INC. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150218135-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2015-08-06 | — | — | US | disclosed |
| US-9085553-B2 | LFA-1 inhibitor and methods of preparation and polymorph thereof | SARcode Bioscience, Inc. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8871935-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140031387-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | SARCODE BIOSCIENCE INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20130144063-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARCODE BIOSCIENCE INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8367701-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120107404-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARCODE BIOSCIENCE INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8080562-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20090298869-A1 | Crystalline pharmaceutical and methods of preparation and use thereof | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218135-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | VCAM1, ICAM1, HLA-DRB1 | ITGB2 14/4885ICAM1 2/4885ITGAL 8/4885 |
| US-20120107404-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | VCAM1, ICAM1, HLA-DRB1 | ITGB2 14/4885ICAM1 2/4885ITGAL 8/4885 |
| US-20160368902-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | VCAM1, ICAM1, HLA-DRB1 | ITGB2 14/4885ICAM1 2/4885ITGAL 8/4885 |
| US-20140031387-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | ITGB1, ITGA1, VCAM1 | ITGB2 10/4885ICAM1 7/4885ITGAL 4/4885 |
| US-20130144063-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | VCAM1, ICAM1, HLA-DRB1 | ITGB2 14/4885ICAM1 2/4885ITGAL 8/4885 |
| US-20090298869-A1 | Crystalline pharmaceutical and methods of preparation and use thereof | VCAM1, ICAM1, HLA-DRB1 | ITGB2 14/4885ICAM1 2/4885ITGAL 8/4885 |
| US-20230331711-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | VCAM1, ICAM1, HLA-DRB1 | ITGB2 14/4885ICAM1 2/4885ITGAL 8/4885 |
| US-20150336939-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | ITGB1, ITGA1, VCAM1 | ITGB2 10/4885ICAM1 7/4885ITGAL 4/4885 |
| US-20180118726-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | ITGB1, ITGA1, VCAM1 | ITGB2 10/4885ICAM1 7/4885ITGAL 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.